GLM101
PMM2-CDG (CDG-Ia)
Phase 2bActive
Key Facts
About Glycomine
Glycomine is a private, pre-revenue biotech advancing a novel substrate replacement platform for rare diseases. Its lead program, GLM101, is in a global Phase 2b trial for PMM2-CDG, representing the first potential disease-modifying therapy for this severe condition. The company is well-capitalized following a $115M Series C financing in April 2025, which is funding the pivotal-stage development of GLM101. Glycomine's approach aims to bypass genetic deficiencies by delivering missing substrates or enzymes, with potential application across a range of rare metabolic disorders.
View full company profile